Task Force on Repurposing of Drugs for COVID19

Assessment of Patent related barriers for Indian manufacturers

The TFORD-COVID19-India has commissioned M/s Gnanlex Hermeneutics Private Limited (Gnanlex) to carry out patent searches and provide their opinion on the patent landscape in India for the drug candidates considered by the TFORD-COVID19-India and also provide insights into the the freedom-to-operate status for Indian manufacturers. Thanks to Gnanlex for providing timely assistance. This section is edited by Dr Vidula Walimbe (TechEx.in at Venture Center).

Reports from Gnanlex Hermeneutics Pvt Ltd (Released on 28 June 2020)

• • • Drug Candidates
      • • 1.  Chloroquine
          2.  Hydroxychloroquine
          3.  Remdesivir  
          4.  Lopinavir/Ritonavir
          5.  Favipiravir
          6.  Baloxavir Marboxil
          7.  Darunavir
          8.  Ribavarin + IFN-beta : Combination
          9.   Galidesivir  
          10.  Oseltamivir  
          11.  Umifenovir 
          12.  Camostat mesylate
          13.  Ruxolitinib
          14.  IFN-beta  
          15.  Tocilizumab 
          16.  Ustekinumab 
          17.  Nigericin
          18.  Teicoplanin  
          19.  Ivermectin
          20.  Baricitinib 
          21.  Tofacitinib 
          22.  Dexamethasone
          23.  Sarilumab
          24.  Sepsivac
          25.  Ulinastatin 
          26.  Nitazoxanide 
          27.  Enaxoparin 
          28.  Famotidine 
          29.  ACEi and ARB : Lisinopril| Losartan
          30.  rhACE protein 

• • • Medicinal Herbs 
      • • 1.  Tinospora cordifolia 
          2.  Glycyrrhiza glabra  
          3.  Withania somnifera 
          4.  Zingiber officinale  
          5.  Andrographis paniculata  
          6.  Artemisia annua
          7.  Cissampelos pareira  
          8.  Vitis vinifera 
          9.  Myrica cerifera